Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot dose escalation study of FFP104 in primary biliary cirrhosis
2014-001638-27Phase 2Completed
- Sponsor
- Fast Forward Pharmaceuticals BV
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FFP104 in primary biliary cholangitis (PBC), sponsored by Fast Forward Pharmaceuticals BV. Started Jul 2014; status: completed.
02
Drugs
FFP104
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2014-001638-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001638-27.